Novel inhibitors

You can also try the following methods, and our professionals will serve you Customized Consultation

Cat. No.	Product Name	Field of Application
DCC4792	Smart-h	Potent inhibitor of microtubule polymerization More description
DCC4791	Smapp1	Novel activator of PP1, inducing HIV-1 transcription, reactivation of latent HIV-1 in chronically infected cells, and CDK9 phosphorylation More description
DCC4790	Smac127	Proapoptotic and anti-inflammatory agent, inducing apoptosis by inhibiting apoptosis proteins (IAPs) More description
DCC4789	Sma-12b	Novel inhibitor of IL-1 More description
DCC4788	Sm4487	Novel potent and selective inhibitor of galactokinase (GALK1) More description
DCC4787	Sm-337	Non-peptidic Smac mimetic, binding to XIAP, cIAP-1 and cIAP-2 proteins with higher affinities in cell growth inhibition in the MDA-MB-231 cell line More description
DCC4786	Sm-131	Novel Potent, Cell-Permeable, Conformationally Constrained Second Mitochondria Derived Activator of Caspase (Smac) Mimetic More description
DCC4785	Sm-130686	Potent, orally-active agonist of the ghrelin/growth hormone secretagogue receptor (GHSR) and growth hormone secretagogue More description
DCC4784	Slupp-417	Novel efflux pump inhibitor (EPI) More description
DCC4783	Slupp-225	Novel efflux pump inhibitor (EPI) More description
DCC4782	Slr080811	Novel SphK2-selective inhibitor More description
DCC4781	Slp7111228	Novel selective SphK1 inhibitor More description
DCC4780	Slp120701	Novel SphK2-selective inhibitor with improved half-life to 8 h in mice More description
DCC4779	Slm6071469	Novel potent SphK2-selective inhibitor (Ki = 89 nM, 73-fold SphK2-selective) with validated in vivo activity More description
DCC4778	Sll-039	Novel highly selective and potent κ opioid agonist (κ, Ki = 0.47 nM, κ/μ = 682, κ/δ = 283) More description
DCC4777	Slk/stk10-in-31	Novel Potent Dual inhibitor of SLK (STE20-like kinase) and STK10 (serine/threonine kinase 10) More description
DCC4776	Slec-8	Potential synthetic lethal lead, targeting E-cadherin-deficient cells More description
DCC4775	Sl910102	Novel nonpeptide AT1 receptor antagonist, acting as a modulator on RAAS and KKS activation during COVID-19 More description
DCC4774	Sl-651498	Full agonist of GABAA receptors containing α2 and α3 subunits, and partial agonist of α1 and α5 subunits. More description
DCC4773	Sl-3-19	Novel microtubule-destabilizing agent, exerting potent antitumor activity against esophageal squamous cell carcinoma More description
DCC4772	Sl-1-73	Novel microtubule-destabilizing agent, exerting potent antitumor activity against esophageal squamous cell carcinoma More description
DCC4771	Skp2 Inhibitor C2	First-in-class Specific Inhibitor of Skp2-Mediated p27 Degradation More description
DCC4770	skp Inhibitor C20	Specific Inhibitor of Skp2-Mediated p27 Degradation More description
DCC4769	skp Inhibitor C16	Specific Inhibitor of Skp2-Mediated p27 Degradation More description
DCC4768	Skog102	Novel inhibitor of OLIG2 in glioblastoma More description
DCC4767	Sklb70326	Novel inhibitor of cell-cycle progression, inducing G0/G1 phase arrest and apoptosis in human hepatic carcinoma cells More description
DCC4766	Sklb-677	Novel FLT3 and Wnt/β-catenin signaling inhibitor, displaying potent activity in models of FLT3-driven AML More description
DCC4765	Sklb-329	Novel multikinase inhibitor, potently inhibiting angiogenesis-related kinases including VEGFR1/2/3, and FGFR2, and the Src kinase More description
DCC4764	Sklb-163	Potent anticancer agent, downregulating RhoGDI, activating JNK-1 signaling pathway and caspase-3, and reducing phosphorylated Akt and p44/42 MAPK More description
DCC4763	Sklb050	Biological Active Reagents More description

Novel inhibitors

Customized Consultation X

Your information is safe with us. * Required Fields.